High-dose radiation with Keytruda led to increased infiltration of various immune cells and formation of tertiary lymphoid ...

Formycon will develop, register, manufacture, and supply the product, while Zydus will be responsible for commercialization.

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for ...

Under the terms of this agreement, Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the ...

Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain ...

This degree of success can become a double-edged sword, though. While the drug has thrived since its first approval back in ...

The healthcare stock could skyrocket if ivonescimab obtains approval from regulators, but there's still plenty of risk here.

Finally, Merck is an excellent dividend stock. It offers a juicy forward yield of 3.2% and has increased its payouts by 93.8% ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...